Investing
Japan’s Ajinomoto to buy US-based Forge Biologics for $546 million
© Reuters. Ajinomoto Co. displays the company’s leading product ‘Ajinomoto Monosodium Glutamate Seasoning’ at AJINOMOTO Umami Science Square in Kawasaki, Japan March 18, 2019. REUTERS/Yoshiyasu Shida/File Photo
TOKYO (Reuters) -Japan’s Ajinomoto said on Monday it agreed to acquire U.S.-based genetic medicines maker Forge Biologics Holdings for 82.8 billion yen ($546 million).
The transaction is expected to be completed in December 2023 pending regulatory approvals, Ajinomoto said a release.
Ajinomoto, whose primary business is in seasonings and processed foods, has a healthcare segment that focuses on drugs derived from amino acids.
Forge, based in the U.S. state of Ohio, is a contract development and manufacturing organization (CDMO) for gene-based therapies. Ajinomoto said Forge will integrate with its own AminoScience platform to work on new treatment options for rare diseases.
($1 = 151.7400 yen)
Read the full article here
-
Passive Income7 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Side Hustles6 days ago
How to Be Unapologetically You and Why It Matters
-
Side Hustles7 days ago
How Your Body Language Can Help Win a Disagreement
-
Investing7 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Investing5 days ago
Nvidia CEO Jensen Huang: Demand For Blackwell AI Is Insane
-
Side Hustles7 days ago
OpenAI Raises Record $6.6 Billion, Adds 50 Million New Users
-
Side Hustles5 days ago
Mark Zuckerberg Is Now Second Richest Person in the World
-
Side Hustles6 days ago
With AI Magicx, It’s Like Getting an Entire Creative Team in One Money-Saving AI Tool